WO1995018134A1 - Improvements in or relating to chiral syntheses - Google Patents

Improvements in or relating to chiral syntheses Download PDF

Info

Publication number
WO1995018134A1
WO1995018134A1 PCT/GB1994/002827 GB9402827W WO9518134A1 WO 1995018134 A1 WO1995018134 A1 WO 1995018134A1 GB 9402827 W GB9402827 W GB 9402827W WO 9518134 A1 WO9518134 A1 WO 9518134A1
Authority
WO
WIPO (PCT)
Prior art keywords
phchch
compounds
compound
cdcl
mmol
Prior art date
Application number
PCT/GB1994/002827
Other languages
French (fr)
Inventor
Stephen Graham Davies
Mario Eugenio Cosamino Polywka
David Roy Fenwick
Frank Reed
Original Assignee
Oxford Asymmetry Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP6517861A priority Critical patent/JP2964639B2/en
Application filed by Oxford Asymmetry Limited filed Critical Oxford Asymmetry Limited
Priority to DK95904629T priority patent/DK0736031T3/en
Priority to EP95904629A priority patent/EP0736031B1/en
Priority to AT95904629T priority patent/ATE192449T1/en
Priority to US08/663,257 priority patent/US6037498A/en
Priority to DE69424313T priority patent/DE69424313T2/en
Publication of WO1995018134A1 publication Critical patent/WO1995018134A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/04Formation of amino groups in compounds containing carboxyl groups
    • C07C227/06Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid
    • C07C227/08Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid by reaction of ammonia or amines with acids containing functional groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/14Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/30Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/32Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/085Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/005Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
    • DTEXTILES; PAPER
    • D02YARNS; MECHANICAL FINISHING OF YARNS OR ROPES; WARPING OR BEAMING
    • D02GCRIMPING OR CURLING FIBRES, FILAMENTS, THREADS, OR YARNS; YARNS OR THREADS
    • D02G1/00Producing crimped or curled fibres, filaments, yarns, or threads, giving them latent characteristics
    • D02G1/02Producing crimped or curled fibres, filaments, yarns, or threads, giving them latent characteristics by twisting, fixing the twist and backtwisting, i.e. by imparting false twist
    • D02G1/0286Producing crimped or curled fibres, filaments, yarns, or threads, giving them latent characteristics by twisting, fixing the twist and backtwisting, i.e. by imparting false twist characterised by the use of certain filaments, fibres or yarns

Definitions

  • the present invention is based on our finding that lithio derivatives of such substantially enantiomerically pure N-allylated ⁇ -methylbenzylamines and analogues thereof are particularly useful reagents acting as sources of chiral nucleophiles.
  • R represents a carbocyclic aryl group
  • R 1 represents an organic group
  • R 2 represents a hydrogen atom or an organic group
  • the asterisk denotes that the group R 1 is predominantly in the R- or S- configuration such that the compound (I) is in substantially
  • substantially enantiomerically pure denotes compounds containing at least 80%
  • Carbocyclic aryl groups R may, for example, contain 6-20 carbon atoms, e.g. as in phenyl or naphthyl, and may if desired be substituted, for example by one or more of halo (e.g. chloro, bromo or iodo), hydroxy, lower (e.g. C 1-4 ) alkoxy (e.g. methoxy or ethoxy), lower alkylthio (e.g. methylthio), lower alkylsulphonyl (e.g.
  • halo e.g. chloro, bromo or iodo
  • hydroxy e.g. C 1-4
  • alkoxy e.g. methoxy or ethoxy
  • lower alkylthio e.g. methylthio
  • lower alkylsulphonyl e.g.
  • methylsulphonyl amino, substituted amino (e.g. mono- or di- (lower alkyl) amino such as methylamino or
  • R groups include phenyl and 3,4-dimethoxyphenyl.
  • the group R 1 can be selected from a wide range of organic groupings, including, for example, aliphatic, cycloaliphatic and araliphatic groups, e.g. containing up to 20 carbon atoms and optionally carrying one or more substituents.
  • R 1 may thus, for example, represent a group selected from C 1-10 alkyl such as methyl or ethyl; C 2-10 alkenyl such as vinyl or propenyl; C 3-10 cycloalkyl such as cyclopentyl or cyclohexyl; C 3-10 cycloalkyl - C 1-4 alkyl such as cyclopentylmethyl; C 6-12 aryl - C 1-4 alkyl such as benzyl; and substituted versions of any of the preceding groups, e.g. carrying substituents as described above for R.
  • C 1-10 alkyl such as methyl or ethyl
  • C 2-10 alkenyl such as vinyl or propenyl
  • C 3-10 cycloalkyl such as cyclopentyl or cyclohexyl
  • C 3-10 cycloalkyl - C 1-4 alkyl such as cyclopentylmethyl
  • C 6-12 aryl - C 1-4 alkyl
  • One preferred class of compounds (I), by virtue of ease of availability of starting materials therefor, are those in which R represents optionally substituted phenyl and R 1 represents methyl.
  • R 2 in formula (I) represents an organic group this may, for example, be a lower alkyl group containing 1-10, e.g. 1-6 carbon atoms, as in methyl, ethyl, propyl and butyl groups; a lower (e.g. C 2-10 ) alkenyl group such as vinyl; a carbocyclic aryl group, e.g. containing 6-20 carbon atoms, such as phenyl or naphthyl; or a
  • heterocyclic group e.g. having one or more 5- and/or 6-membered rings and containing one or more heteroatoms selected from O, N and S as in, for example, furyl, thienyl, pyrrolyl, pyridyl, benzothienyl, indolyl, imidazolidinyl or piperidinyl.
  • compounds (I) according to the invention are a useful source of chiral nucleophiles, capable of undertaking highly stereoselective reactions.
  • they may undergo Michael addition to ⁇ , ⁇ -unsaturated carboxylic acid derivatives such as esters, thioesters, amides, thioamides and
  • oxazolidinones with high diastereoselectivity, e.g. as represented by the following sequences in the case of addition to an ⁇ , ⁇ -unsaturated ester:
  • R, R 1 and R 2 are as hereinbefore defined;
  • R 3 represents an organic group;
  • R 4 represents an esterifying group such as a lower alkyl or aralkyl group; and
  • R 5 represents a hydrogen atom or an organic group).
  • R 3 may, for example, be an organic group as hereinbefore described for R, R 1 or R 2 , and may if desired be substituted, e.g. by one or more functional groups such as protected hydroxyl, amino or carboxaldehyde.
  • the esterifying group R 4 in the starting ⁇ , ⁇ -unsaturated ester is preferably chosen to be relatively bulky, e.g. being a tert-butyl group, in order to
  • R 5 represents an organic group this may, for example, be as described for any of R, R 1 , R 2 and R 3 .
  • Michael additions proceed through an enolate intermediate.
  • This may, if desired, be trapped by reaction with an electrophile, for example an alkyl halide, an aldehyde, an imine, a Michael acceptor, or an oxygen electrophile (e.g. molecular oxygen, an epoxide or an oxaziridine - use of such reagents may, for example, permit stereospecific
  • the allylic N-substituent R 2 .CH:CH.CH 2 - in compounds of formulae (Ila) and (IIb) may readily and selectively be removed, e.g. under mildly reductive conditions, for example using an agent such as tris(triphenylphosphine)-rhodium(I) chloride in a solvent such as aqueous
  • acetonitrile, and the resulting secondary amine may be subjected to ⁇ -lactam formation, e.g. according to the sequence
  • esterifying groups for this purpose include, for example, methyl and ethyl.
  • Cyclisation of a compound (IIIa) or (Illb) to form the desired ⁇ -lactam (IVa) or (IVb) may be effected using any convenient cyclisation agent, for example an
  • organometallic compound e.g. a Grignard reagent such as methyl magnesium bromide.
  • a Grignard reagent such as methyl magnesium bromide.
  • Such reactions may conveniently be effected in an aprotic organic solvent, for example an ether such as diethyl ether.
  • N-allyl compounds (Ila) and (IIb) prepared as described above may also be cyclised in accordance with the invention, e.g. using methods generally known in the art, for example to generate 5- and 6-membered
  • R, R 1 , R 2 and the asterisk are as hereinbefore defined, e.g. by reaction with a lithium alkyl such as n-butyllithium, for example in a cyclic ether solvent such as tetrahydrofuran at a temperature of less than 0°C, conveniently at about -78oC.
  • a lithium alkyl such as n-butyllithium
  • a cyclic ether solvent such as tetrahydrofuran at a temperature of less than 0°C, conveniently at about -78oC.
  • compound (I) may advantageously be used in situ without being isolated.
  • R 2 is as hereinbefore defined and X represents a halogen atom such as bromine
  • X represents a halogen atom such as bromine
  • NCH 2 39.17 (CH 2 CO) , 27.84 (C (CH 3 ) 3 , ) 16.35 (NCHCH 3 ) , m/z (CD 366(MH + , 100%) , 310 (8) , 250 (15) , 160 (35) , 146
  • the title compound (14) was obtained by repeating the process of Example 1 using t-butyl 3-(fur-2-yl)propenoate (13) as the Michael acceptor, v max (CHCl 3 )/cm -1 1729s
  • NCH 2 (NCH 2 ), 36.34 (CH 2 CO), 32.85 (CH 3 ) 2 CH), 27.89 (C(CH 3 ) 3 ), 20.83, 20.51 ((CH 3 ) 2 CH), 19.59 (NCHCH 3 ); m/z (CI) 322 (MH + , 100%), 288 (30), 232 (15), 128 (22), 105 (25) ;
  • Example 1 The procedure of Example 1 was repeated using (S)-N-allyl- ⁇ -methylbenzylamine (2) (0.840g, 5.22 mmol), 1.6M butyllithium (2.16 ml, 4.17 mmol) and t-butyl 5-phenyl- (E,E)-pentadienoate (19) (0.800g, 3.48 mmol) as the
  • Example 12 The procedure of Example 12 was repeated using (S)-N-cinnamyl- ⁇ -methylbenzylamine (4) (0.300g, 1.27 mmol), 1.6M butyllithium (0.730 ml, 1.17 mmol), t-butyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mechanical Engineering (AREA)
  • Textile Engineering (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Forging (AREA)
  • Yarns And Mechanical Finishing Of Yarns Or Ropes (AREA)
  • Woven Fabrics (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

Novel compounds of general formula (I) (wherein R represents a carbocyclic aryl group, R1 represents an organic group, R2 represents a hydrogen atom or an organic group, and the asterisk denotes that the group R1 is predominantly in the R- or S- configuration such that the compound is in substantially enantiomerically pure form). The compounds are a useful source of chiral nucleophiles, e.g. undergoing stereoselective Michael addition to α,β-unsaturated carboxylic acid derivatives.

Description

"Improvements in or relating to chiral syntheses" This invention is concerned with new chiral lithium amides and their use in the synthesis of chiral β-amino acids, β-lactams and the like.
Compounds such as (R) - and (S)-α-methylbenzylamine are known to be useful starting materials in the
synthesis of a range of chiral molecules. Thus, for example, N-allyl derivatives thereof have been described in connection with stereoselective syntheses by Bailey et al. in Tet. Lett. 30(39), pp. 5341-5344 (1989) and by
Cardillo et al. in Tet. 47(12/13), pp. 2263-2272 (1991).
The present invention is based on our finding that lithio derivatives of such substantially enantiomerically pure N-allylated α-methylbenzylamines and analogues thereof are particularly useful reagents acting as sources of chiral nucleophiles.
Thus according to one aspect of the invention there are provided compounds of general formula (I)
Figure imgf000003_0001
(wherein R represents a carbocyclic aryl group, R1 represents an organic group, R2 represents a hydrogen atom or an organic group, and the asterisk denotes that the group R1 is predominantly in the R- or S- configuration such that the compound (I) is in substantially
enantiomerically pure form).
The term substantially enantiomerically pure as used herein denotes compounds containing at least 80%,
advantageously at least 90%, and preferably at least 95% of the desired enantiomer.
Carbocyclic aryl groups R may, for example, contain 6-20 carbon atoms, e.g. as in phenyl or naphthyl, and may if desired be substituted, for example by one or more of halo (e.g. chloro, bromo or iodo), hydroxy, lower (e.g. C1-4) alkoxy (e.g. methoxy or ethoxy), lower alkylthio (e.g. methylthio), lower alkylsulphonyl (e.g.
methylsulphonyl), amino, substituted amino (e.g. mono- or di- (lower alkyl) amino such as methylamino or
dimethylamino), carboxy, cyano, lower alkoxycarbonyl (e.g. methoxycarbonyl), carbamoyloxy, sulphamoyl and sulphoxy. Preferred R groups include phenyl and 3,4-dimethoxyphenyl.
The group R1 can be selected from a wide range of organic groupings, including, for example, aliphatic, cycloaliphatic and araliphatic groups, e.g. containing up to 20 carbon atoms and optionally carrying one or more substituents. R1 may thus, for example, represent a group selected from C1-10 alkyl such as methyl or ethyl; C2-10 alkenyl such as vinyl or propenyl; C3-10 cycloalkyl such as cyclopentyl or cyclohexyl; C3-10 cycloalkyl - C1-4 alkyl such as cyclopentylmethyl; C6-12 aryl - C1-4 alkyl such as benzyl; and substituted versions of any of the preceding groups, e.g. carrying substituents as described above for R.
One preferred class of compounds (I), by virtue of ease of availability of starting materials therefor, are those in which R represents optionally substituted phenyl and R1 represents methyl.
Where R2 in formula (I) represents an organic group this may, for example, be a lower alkyl group containing 1-10, e.g. 1-6 carbon atoms, as in methyl, ethyl, propyl and butyl groups; a lower (e.g. C2-10) alkenyl group such as vinyl; a carbocyclic aryl group, e.g. containing 6-20 carbon atoms, such as phenyl or naphthyl; or a
heterocyclic group, e.g. having one or more 5- and/or 6-membered rings and containing one or more heteroatoms selected from O, N and S as in, for example, furyl, thienyl, pyrrolyl, pyridyl, benzothienyl, indolyl, imidazolidinyl or piperidinyl.
As noted above, compounds (I) according to the invention are a useful source of chiral nucleophiles, capable of undertaking highly stereoselective reactions. Thus, for example, they may undergo Michael addition to α,β-unsaturated carboxylic acid derivatives such as esters, thioesters, amides, thioamides and
oxazolidinones, with high diastereoselectivity, e.g. as represented by the following sequences in the case of addition to an α,β-unsaturated ester:
Figure imgf000005_0002
and
Figure imgf000005_0001
(where R, R1 and R2 are as hereinbefore defined; R3 represents an organic group; R4 represents an esterifying group such as a lower alkyl or aralkyl group; and R5 represents a hydrogen atom or an organic group).
In the above formulae R3 may, for example, be an organic group as hereinbefore described for R, R1 or R2, and may if desired be substituted, e.g. by one or more functional groups such as protected hydroxyl, amino or carboxaldehyde.
The esterifying group R4 in the starting α,β-unsaturated ester is preferably chosen to be relatively bulky, e.g. being a tert-butyl group, in order to
minimise competing 1,2-addition of the chiral nucleophile to the carbon atom of the ester carbonyl group.
Where R5 represents an organic group this may, for example, be as described for any of R, R1, R2 and R3.
It will be appreciated that such Michael additions proceed through an enolate intermediate. This may, if desired, be trapped by reaction with an electrophile, for example an alkyl halide, an aldehyde, an imine, a Michael acceptor, or an oxygen electrophile (e.g. molecular oxygen, an epoxide or an oxaziridine - use of such reagents may, for example, permit stereospecific
hydroxylation of the carbon atom α- to the ester
grouping).
Reaction sequences of the above types and the products thereof, e.g. compounds of formulae (Ila) and (lib) are novel and represent further features of the invention.
The allylic N-substituent R2.CH:CH.CH2- in compounds of formulae (Ila) and (IIb) may readily and selectively be removed, e.g. under mildly reductive conditions, for example using an agent such as tris(triphenylphosphine)-rhodium(I) chloride in a solvent such as aqueous
acetonitrile, and the resulting secondary amine may be subjected to β-lactam formation, e.g. according to the sequence
Figure imgf000006_0001
or
Figure imgf000007_0001
It may be advantageous to subject the secondary amine (IIIa) or (Illb) to transesterification prior to β- lactam formation, e.g. using techniques standard in the art, such as acid-catalysed transesterification, in order to introduce a less labile esterifying group R4' which will enhance elimination of the -OR4' moiety;
representative esterifying groups for this purpose include, for example, methyl and ethyl.
Cyclisation of a compound (IIIa) or (Illb) to form the desired β-lactam (IVa) or (IVb) may be effected using any convenient cyclisation agent, for example an
appropriate organometallic compound, e.g. a Grignard reagent such as methyl magnesium bromide. Such reactions may conveniently be effected in an aprotic organic solvent, for example an ether such as diethyl ether.
N-allyl compounds (Ila) and (IIb) prepared as described above may also be cyclised in accordance with the invention, e.g. using methods generally known in the art, for example to generate 5- and 6-membered
heterocycles.
The preparation of β-lactams of formulae (IVa) and (IVb) by the above-described processes is novel and represents a further feature of the present invention.
Compounds of formula (I) in accordance with the invention may conveniently be prepared from a
corresponding amine of formula (V)
Figure imgf000008_0001
(where R, R1, R2 and the asterisk are as hereinbefore defined), e.g. by reaction with a lithium alkyl such as n-butyllithium, for example in a cyclic ether solvent such as tetrahydrofuran at a temperature of less than 0°C, conveniently at about -78ºC. The thus-formed
compound (I) may advantageously be used in situ without being isolated.
Starting materials of formula (V) may themselves be prepared by, for example, converting an amine of formula (VI)
Figure imgf000008_0002
(where R, R1 and the asterisk are as hereinbefore defined) to a corresponding lithium amide, e.g. by reaction with a lithium alkyl as described above, and reacting this with an allyl derivative of formula (VII)
Figure imgf000008_0003
(where R2 is as hereinbefore defined and X represents a halogen atom such as bromine) e.g. using as solvent an alcohol such as methanol.
The following non-limitative examples serve to illustrate the invention.
Figure imgf000009_0001
Figure imgf000010_0001
Figure imgf000011_0001
Figure imgf000012_0001
Figure imgf000013_0001
Figure imgf000014_0001
Preparation of starting materials
Preparation 1 (S)-N-Allyl-α-methγlbenzylamine (2 )
A solution of (S)-α-methylbenzylamine (1) (10.0g, 82.5 mmol) in anhydrous tetrahydrofuran (100 ml) was cooled to 0°C and 1.6 M butyllithium (61 ml, 90.8 mmol) was added dropwise via a syringe. The resulting orange lithium amide solution was stirred for 30 minutes at 0°C, after which allyl bromide (7.2 ml, 99.0 ml) was added. The reaction mixture was stirred for a futher 4 hours at 0°C and then quenched with methanol. The solvent was removed under reduced pressure to afford an orange residue. This was diluted with ethyl acetate (100 ml) and washed with saturated sodium bicarbonate (2 × 50 ml), water (50 ml) and brine (50 ml), dried (magnesium sulphate) and
filtered, and the solvent was evaporated under reduced pressure. Purification of the residue by silica gel chromatograpy [ethyl acetate/petroleum ether (1:4);
Rf0.25] afforded the mono-allylated amine as an orange oil. Distillation [110°C, 20 mmHg] gave the title
compound (2) as a colourless oil (8.6 g, 65%). [α]D 21 -63.2 (c 1.36, CHCl3); ʋmax (CHCl3) /cm-1 1643 m (C=C); δH
(300MHz; CDCl3) 7.42-7.22 (5H, m, Ph), 5.93 (1H, ddt, J = 17.2, 10.2 and 6.0, CH=CH2), 5.16 (1H, dd, J = 17.2 and 1.5, trans CH=CH2), 5.10 (1H, d, J = 10.2, cis CH=CH2), 3.83 (1H, q, J = 6.6, PhCfiCH3), 3.13 (2H, d, J = 6.1, NCH2), 1.40 (3H, d, J = 6.6, PhCHCH3); δc (50 MHz; CDCl3) 145.80 (Ph:Cipso), 137.26 (CH=CH2), 128.67, 126.85
(Ph:Cortho,Cmeta), 127.14 (Ph:Cpara), 115.84 (CH=CH2), 57.56 PhCHCH3), 50.24 (NCH2), 24.23 (PhCHCH3); m/z (Cl) 162 (MH+, 100%), 146 (50), 105 (12), 58 (20); (Found: C, 82.07; H, 9.11; N, 8.99. C11H15N requires C, 81.94; H,9.38; N,
8.69%). Preparation 2
(S)-(E,E)-N-Hexa-2,4-dienyl-α-methylbenzylamine (3 ) To a solution of (S)-α-methylbenzylamine (1) (1.00g, 8.25 mmol) in ethanol (20 ml) was added 2,4-hexadienal (0.833 g, 8.66 mmol) and the resulting mixture was refluxed for 1 hour. The solution was cooled to 0°C and sodium borohydride (0.468g, 12.38 mmol) was slowly added in portions. This solution was allowed slowly to warm to room temperature overnight (16 hours) after which the ethanol was removed under reduced pressure and the residue dissolved in ethyl acetate (50 ml). This
solution was washed with brine (30 ml), dried (magnesium sulphate), filtered and evaporated to give an orange oil. This was purified by flash chromatograpy on silica gel [ethyl acetate/petroleum ether (1:4)], followed by distillation under reduced pressure [130°C, 1 mmHg] to afford the title compound (3) as a colourless oil (1.51 g, 91%). δH (300 MHz; CDCl3) 7.37-7.21 (5H, m, Ph), 6.08 (2H, m, CH=CH-CH=CH), 5.63 (2H, m, CH=CH-CH=CH), 3.80 (1H, q, J = 6.6, PhCHCH3), 3.10 (2H, d, J = 6.5, NCH2), 1.74 (3H, d, J = 6.8, CH=CHCH3), 1.49 (1H, br s, NH), 1.36 (3H, d, J=6.8, PhCHCH3).
Preparation 3
(S)-N-cinnamyl-a-methylbenzylamine (4) To a solution of (S)-α-methylbenzylamine (1) (0.500 g, 4.13 mmol) in toluene (20 ml) were added N-ethlydiisopropylamine (0.719 ml, 4.13 mmmol) and cinnamyl chloride (0.575 ml, 4.13 mmol). The mixture was refluxed overnight, after which the toluene was removed under reduced pressure. The residue was partitioned between ethyl acetate (50 ml) and saturated sodium bicarbonate solution (30 ml) and the organic layer was washed with brine (30 ml), dried (magnesium suphate) and removed under reduced pressure to afford a yellow oil. This was purified by flash chromatograpy on silica gel [ethyl acetate/petroleum ether (1:4) to give the title compound (4) as a colourless oil (0.456 g, 47%). δH (200 MHz;
CDCl3) 7.41-7.20 (10H, m, Ph), 6.50 (1H, d, J = 15.9, PhCH=CH), 6.30 (1H, dt, J = 15.9 and 6.1, PhCH=CH), 3.88 (1H, q, J = 6.6, PhCHCH3), 3.29 (2H, d, J = 6.5, NC(H2), 1.56 (1H, br s, NH), 1.42 (3H, d, J = 6.8, PhCHCH3).
Formation and reaction of chiral lithium amides
Example 1 (3S,αS)-t-Butyl 3-(N-allyl-α-methylbenzylamino) butanoate
A solution of (S)-N-allyl-α-methylbenzylamine (2) (0.75 mmol) in anhydrous tetrahydrofuran (5 ml) was cooled to -78°C and 1.6 M butyllithium (0.60 mmol) was added
dropwise via a syringe. The resulting pink lithium amide solution was stirred for 1 hour at -78°C. The Michael acceptor t-butyl crotonate (5) (0.50 mmol) was then slowly added, dropwise, as a solution in anhydrous
tetrahydrofuran (2 ml) via a cannula and stirring was continued at -78°C for a further 1 hour. The reaction was quenched by the addition of saturated aqueous ammonium chloride. The solvent was evaporated under reduced pressure and the residue was diluted with ethyl acetate (30 ml) and washed with water (30 ml) and brine (30 ml), dried (magnesium suphate) and filtered, and the solvent was evaporated under reduced pressure to afford a clear oil. This material was then subjected to flash
chromatography on silica gel, to yield the title compound (6). [α]D 21 +16.9(C 1.80, CHCl3); ʋmax (CHCl3) /cm-1 1729s (C=P), 1641m (C=C); δH (300MHz; CDCl3 ) 7.39-7.18 (5H, m, Ph), 5.84 (1H, m, CH=CH2) , 5.14 (1H, ddd, J = 17.2, 3.5 and 1.7, trans CH=CH2) , 5.01 (1H, ddd, J = 10.1, 3.3 and 1.6, cis CH=CH2) , 3.95 (1H, q, J = 6.8, PhCHCH3), 3.47 (2H, m, NCH2), 3.16 (1H, m NCHCH2) , 2.32, 2.09 (2H, ABX system, JAB = 14.3, JAX = 6.1, JBX = 8.3 CH2CO) , 1.42 (9H, s, (CH3)3C), 1.39 (3H, d, J = 6.8, PhCHCH3) , 1.05 (3H, d, J = 6.7, CH3CHCH2) ; δc (50MHz; CDCl3) 172.20 (C=O) , 145.45 (Ph:Cipso), 139.55 (CH=CH2), 128.23, 127.76
(Ph:Cortho,Cmeta), (Ph:C) , 126.75 (Ph:Cpara), 115.35
(CH=CH2), 79.86 (C(CH3)3) , 58.06, 50.67 (CHN) , 48.86
(NCH2), 41.20 (CH2CO) , 27.98 (C(CH3)3) , 19.58, 17.16
(NCHCH3) ; m/z (Cl) 304 (MH+, 100%), 248 (12) , 188 (30), 142 (25), 105 (22), 84 (32) ; (Found: C, 75.03; H, 9.89; N, 4.87. C19H29NO2 requires C, 75.21; H,9.63; N, 4.62%) . Example 2
(3R,αS)-t-Butyl 3-(N-allyl-α-methylbenzylamino)-3-phenylpropionate ( 8 ) The title compound (8) was obtained by repeating the process of Example 1 using t -butyl cinnamate (7) as the
Michael acceptor. [α]D 21 -2.1 (c 3.24, CHCl3) ; ʋmax
(CHCl3)/cm-1 1730s (C=O), 1641m (C=C) ; δH (300 MHz; CDCl3) 7.43-7.19 (10H, m, Ph) , 5.81 (1H, m, CH=CH2) , 5.15 (1H, ddd, J = 17.2, 3.5 and 1.6, trans CH=CH2), 5.04 (1H, ddd,
J = 10.2, 3.1 and 1.4, cis CH=CH2), 4.45 (1H, dd, PhCHCH2) ,
4.04 (1H, q, J = 6.7,PhCHCH3), 3.16 (2H, m,NCH2), 2.78, 2.60 (2H, ABX system, JAB = 14.7, JAX = 6.2, JBX = 8.9 CH2CO) , 1.30 (9H, s, (CH3)3C), 1.17 (3H, d, J = 6.8,
PhCHCH3) , δc (50MHz; CDCl3) 171.59 (C=O), 145.20, 141.92
(Ph:Cipso), 139.23 (CH=CH2) , 128.39, 128.29, 128.06, 127.80 (Ph:Cortho,Cmeta), 127.31, 126.81 (Ph:Cpara) , 115.90
(CH=CH2), 80\23 (C(CH3)3), 59.19, 56.21 (CHN) , 49.76
(NCH2) , 39.17 (CH2CO) , 27.84 (C (CH3) 3, ) 16.35 (NCHCH3) , m/z (CD 366(MH+, 100%) , 310 (8) , 250 (15) , 160 (35) , 146
(30) , 105 (25) ; (Found: C, 78.77; H, 8.81; N, 3.-62.
C24H31NO2 requires C, 78.87; H,8.55; N, 3.83%) . Example 3
(3R,αS)-t-Butyl 3-(N-allyl-α-methylbenzylamino) penanoate (10)
The title compound (10) was obtained by repeating the process of Example 1 using t-butyl 2-pentenoate (9) as the Michael acceptor. [α]D 21 +18.5 (c 1.88, CHCl3) ; ʋmax (CHCl3)/cm-1 1729s (C=O), 1641m (C=C) ; δH (300 MHz; CDCl3) 7.36-7.18 (5H, m, Ph), 5.86 (1H, m, CH=CH2) , 5.19 (1H, ddd, J = 17.2, 3.5 and 1.8, trans CH=CH2), 5.12 (1H, ddd,
J = 10.2, 3.2 and 1.7, cis CH=CH2) , 3.94 (1H, q, J = 6.9, PhCHCH3) , 3.20 (1H, m, CH3CH2CH) , 3.15 (2H, m,NCH2) , 2.03, 1.96 (2H, ABX system, JAB = 14.5, JAX = 5.2, JBX = 8.3, CH2=CO) , 1.41 (9H, S, (CH3)3), 1.40 (3H, d, J = 6.9,
PhCHCH3), 1.40 (2H, m, CH3CH2) , 0.92 (3H, t, J = 7.3, CH3CH2) ; δc (50 MHz; CDCl3) 172.65 (C=O) , 144.61 (Ph:Cipso) , 139.60 (CH=CH2) , 128.24, 127.91 (Ph:Cortho/ Cmeta), 126.88 (Ph:Cpara) , 115.35 (CH=CH2), 79.82 (C(CH3)3), 58.28, 56.32 (CHN) , 48.74 (NCH2), 37.87 (CH2CO), 27.96 (C(CH3)3), 25.67
(CH3CH2) , 20.66 (NCHCH3), 11.60 (CH3CH2) ; m/z (Cl) 318 (MH+, 100%), 288 (8), 262 (10), 202 (12) , 105 (15) ; (Found: C, 75.88; H, 9.71; N, 4.42. C20H31NO2 requires C, 75.67; H,
9.84; N, 4.41%) .
Example 4
(3R,αS)-t-Butyl 3-(N-allyl-α-methylbenzylamino)-4-hexenoate (12)
The title compound (12) was obtained by repeating the process of Example 1 using t-butyl sorbate (11) as the Michael acceptor. [α]D 21 +2.7 (c 1.67, CHCl3); ʋmax
(CHCl3) /CM-1 1729s (C=O], 1656m (C=C), 1644m (C=C); δH (300 MHz; CDCl3) 7.39-7.18 (5H, m, Ph), 5.79 (1H, m,
CH=CH2) , 5.51 (2H, m, CH3CH=CH), 5.08 (1H, ddd, J = 17.2, 3.4 and 1.7, trans CH=CH2), 5.00 (1H, ddd, J = 10.1, 3.1 and 1.5, cis CH=CH2) , 4.01 (1H, q, J = 6.8, PhCHCH3) , 3.83 (1H, m, CHCH2CO) , 3.13 (2H, m, NCH2) , 2.42, 2.27 (2H, ABX system, JAB = 14.2, JAX = 6.5, JBX = 8.4, CH2CO) , 1.71 (3H, d, J = 5.0, CH3C=C), 1.41 (9H, S, (CH3)3C) , 1.38 (3H, d, J = 6.8, PhCHCH3) ; δc (50 MHz; CDCl3) 171.66 (C=O), 145.50 (Ph:Cipso), 139.19 (CH=CH2) , 130.93 (CH3C=C), 128.16,
127.80 (Ph:Cortho, Cmeta), 126.99, 126.67 (Ph:Cpara, CH3C=C), 115.54 (CH=CH2) , 79.94 (C(CH3)3), 57.22, 57.07 (CHN), 49.62 (NCH2), 39.83 (CH2CO), 27.97 (C(CH3)3), 18.36, 17.84 (CH3C=C, NCHCH3) ; m/z (CD 330 (MH+, 100%) , 274 (10) , 214
(35), 110 (25) .
Example 5 (3R, αS)-t-Butyl 3-(N-allyl-α-methylbenzylamino)-3-(fur-2-yl)-propionate (14)
The title compound (14) was obtained by repeating the process of Example 1 using t-butyl 3-(fur-2-yl)propenoate (13) as the Michael acceptor, vmax (CHCl3)/cm-1 1729s
(C=O) , 1641m (C=C) ; δH (300 MHz; CDCl3) 7.41-7.18 (6H, m, Ph, OCH=CH), 6.35 (1H, dd, J = 1.9 and 3.2, OCH=CH), 6.14 (1H, d, J = 3.2, OC=CH), 5.69 (1H, m, CH=CH2), 5.10 (1H, dd, J = 17.2 and 1.6, trans CH=CH2), 5.04 (1H, dd, J = 10.2 and 1.6, cis CH=CH2), 4.60 (1H, t, J = 7.6, NCHCH2), 4.08 (1H, q, J = 6.8,PhCHCH3), 3.14 (2H, m,NCH2), 2.78, 2.69 (2H, ABX system, JAB = 15.0, JAX = 8.0, JBX = 7.4, CH2=CO), 1.42 (9H, s, (CH3)3), 1.10 (3H, d, J =
6.8, PhCHCH3) ; δc (50 MHz; CDCl3) 170.98 (C=O) , 155.32 (OC=CH), 145.64 (Ph:Cipso), 141.59 (OCH), 138.30 (CH=CH2),
128.20, 127.76 (Ph:Cortho, Cmeta), 126.68 (Ph:Cpara), 116.42, (CH=CH2), 110.32 (OCH=CH), 107.16 (OCH=CH), 80.38
(C(CH3)3), 56.29, 51.86 (CHN), 50.09 (NCH2), 38.41
(CH2CO), 27.96 (C(CH3)3), 16.91 (NCHCH3) ; m/z (Cl) 356 (MH+, 100%), 300 (10), 240 (20), 194 (10), 160 (25) . Example 6
(3R, αS)-t-Butyl 3-(N-allyl-α-methylbenzylamino)-4-methylpentanoate (16)
The title compound (16) was obtained by repeating the process of Example 1 using t-butyl 4-methyl-2-pentenoate (15) as the Michael acceptor. [α]D 21 +52.7 (c 1.85,
CHCl3) ; vmax (CHCl3)/cm -1 1729s (C=O), 1641w (C=C); δH (300MHz; CDCl3) 7.34-7.20 (5H, m, Ph), 5.87 (1H, m,
CH=CH2), 5.23 (1H, ddd, J = 17.2, 3.2 and 1.8, trans
CH=CH2), 4.88 (1H, dd, J = 10.1 and 1.0, cis CH=CH2), 3.91 (1H, q, J = 7.0, PhCHCH3), 3.15 (1H, m, CHCH2CO), 3.10 (2H,m,NCH2), 1.97, 1.87 (2H, ABX system, JAB = 16.0, JAX = 8.3, JBX = 3.2, CH2CO), 1.63 (1H, m, (CH3)2CH), 1.42 (3H, d, J = 7.0, PhCHCH3), 1.41 (9H, s, (CH3)3C), 1.00 (3H, d, J = 6.6, (CH3)2CH), 0.83 (3H, d, (CH3)2CH); δc (50 MHz;
CDCl3) 172.86 (C=0), 143.52, (Ph:Cipso), 139.43 (CH=CH2), 128.20, 128.12 (Ph:Cortho, Cmeta), 126.92, (Ph:Cpara), 115.46 (CH=CH2), 79.82 (C(CH3)3), 58.97, 58.42 (CHN) , 49.59
(NCH2), 36.34 (CH2CO), 32.85 (CH3)2CH), 27.89 (C(CH3)3), 20.83, 20.51 ((CH3)2 CH), 19.59 (NCHCH3); m/z (CI) 322 (MH+, 100%), 288 (30), 232 (15), 128 (22), 105 (25) ;
(Found: C, 76.12; H, 10.36. C21H33NO2 requires C, 76.09; H, 10.03%) .
Example 7
(3S, αS)-t-Butyl 3-(N-allyl-α-methylbenzylamino)-4-phenylbutanoate (18)
The procedure of Example 1 was repeated using (S)-N-allyl-α-methylbenzylamine (2) (0.750g, 4.7 mmol), 1.6M butyllithium (2.52 ml, 4.0 mmol) and t-butyl 4-phenyl-2-butenoate (17) (0.678g, 3.1 mmol) as the Michael
acceptor. Flash chromatography on silica gel [ethyl acetate/petroleum ether (1:49)] afforded the title compound (Rf 0.20) as a colourless oil (0.968g, 82%) . δH (300 MHz; CDCl3) 7.40-7.15 (5H, m, Ph) , 5.96-5.82 (1H, m, NCH2CH=CH2), 5.19 (1H, dd, J = 17.3 and 1.3, trans
CH=CH2), 5.09 (1H, dd, J = 10.1 and 1.3, cis CH=CH2), 3.95 (1H, q, J = 6.7, PhCHCH3), 3.67-3.56 (1H, m, PhCH2CH),
3.38-3.13 (2H, m, NCH2), 2.77 (1H, dd, J = 14.7 and 7.1, CH2CO2), 2.55 (1H, dd, J = 14.7 and 6.0, CH2CO2), 2.08 (2H, d, J = 7.1, PhCH2), 1-42 (9H, s, (CH3) 3C), 1.20 (3H, d, J = 6.7, PhCHCH3).
Example 8
(3R, αS)-t-Butyl 3-(N-allyl-α-methylbenzylamino)-5-phenyl-4-pentenoate (20)
The procedure of Example 1 was repeated using (S)-N-allyl-α-methylbenzylamine (2) (0.840g, 5.22 mmol), 1.6M butyllithium (2.16 ml, 4.17 mmol) and t-butyl 5-phenyl- (E,E)-pentadienoate (19) (0.800g, 3.48 mmol) as the
Michael accetor. Flash chromatography on silica gel
[ethyl acetate/petroleum ether (1:19)] afforded the title compound (20) as a colourless oil (1.33g, 98%). δH (200 MHz; CDCl3) 7.48-7.21 (10H, m, Ph), 6.48 (1H, d, J = 16.0, PhCH=CH), 6.25 (1H, dd, J = 16.0 and 7.4, PhCH=CH), 5.85 (1H, m, NCH2CH=CH2), 5.15 (1H, app. dd, J = 17.3 and 1.6, trans NCH2CH=CH), 5.07 (1H, app. dd, J = 10.3 and 1.5, cis NCH2CH=CH2), 4.09 (2H, m, PhCHCH3 and PhCH=CHCH), 3.22 (2H, d, J = 6.1, NCH2), 2.56 (1H, dd, J = 14.3 and 6.6, CH2CO2), 2.42 (1H, dd, J = 14.3 and 8.2, CH2CO2), 1.43 (3H, m, PhCHCH3), 1.42 (9H, s, (CH3)3C).
The same diastereoisomer (20) was obtained when t-butyl 5-phenyl(Z,E)-pentadienoate (21) was used as the Michael acceptor. Example 9
(3R,αS)-t-Butyl 3-(N-cinnamyl-α-methylbenzylamino)-3-phenylpropionate (22)
(S)-N-cinnamyl-α-methylbenzylamine (4) (0.100g, 0.42 mmol), 1.6M butyllithium (0.242 ml, 0.39 mmol) and t-butyl cinnamate (7) (0.072g, 0.35 mmol) were reacted according to the procedure of Example 1. Flash
chromatography of the product on silica gel [ethyl acetate/petroleum ether (1:49)] afforded the title compound (Rf 0.3) as a colourless oil (0.145g, 78%). δH (300 MHz; CDCl3) 7.50-7.18 (15H, m, Ph), 6.42 (1H, d, J = 16.0, PhCH=CH), 6.11 (1H, dt, J = 16.0 and 6.2, CH=CHPh), 4.53 (1H, dd, J = 8.7 and 6.4, PhCHCH2), 4.07 (1H, q, J = 6.7, PhCHCH3), 3.32 (2H, dd, J = 6.2 and 1.1, NCH2), 2.83 (1H, dd, J = 14.6 and 6.4, CH2CO2), 2.62 (1H, dd, J = 14.6 and 8.7, CH2CO2), 1.31 (9H, s, (CH3)3C), 1.27 (3H, d, J =
6.7, PhCHCH3).
Example 10
(3R, αS) -t-Butyl 3- (N-hexa-2 , 4-dienyl-α-methylbenzylamino) -4-hexenoate (23)
(S)-(E,E)-N-Hexa-2,4-dienyl-α-methylbenzylamine (3)
(0.500g, 2.49 mmol), 1.6M butyllithium (1.35 ml, 2.16 mmol) and t-butyl sorbate (11) (0.279g, 1.66 mmol) were reacted according the procedure of Example 1. Flash chromatography of the product on silica gel [ethyl acetate/petroleum ether (1:19)] afforded the title compound as a colourless oil (0.791g, 72%). δH (200 MHz; CDCl3) 7.39-7.18 (5H, m, Ph), 6.12-5.93 (2H, m, CH=CH-CH=CH), 5.69-5.41 (4H, m, CH3CH=CH and CH=CH-CH=CH), 4.0 (1H, q, J = 6.8, PhCHCH3), 3.87-3.75 (1H, m, CH3CH=CHCH), 3.21-3.09 (2H, m, NCH2), 2.40 (1H, dd, J = 14.1 and 6.4, CH2CO2) , 2.25 (1H, dd, J = 14.1 and 8.5, CH2CO2), 1.76- 1.71 (6H, m, CH3CH=CHCH and CH=CHCH3) , 1.41 (9H, s,
(CH3)3C) , 1.37 (3H, d, J = 6.7, PhCHCH3) .
Example 11
(3S,αR)-t-Butyl 3-(N-allyl-α-methylbenzylamino)-4-pentenoate (26)
A solution of (R)-N-allyl-α-methylbenzylamine (24)
(1.78g, 11.1 mmol) in anhydrous tetrahydrofuran (20 ml) was cooled to -78°C and 1.6M butyllithium (6.00 ml, 9.5 mmol) was added dropwise via a syringe. The resulting orange lithium amide solution was stirred at -78°C for 1 hour. A solution of t-butyl pentadienoate (25) (1.137g, 7.4 mmol) in anhydrous tetrahydrofuran (15 ml) was then added via a cannula and the solution was stirred for a further 1 hour. The reaction was quenched by the
addition of saturated aqueous ammonium chloride solution and the solution was allowed to warm to room temperature. Ethyl acetate (50 ml) was added, followed by brine (10 ml) . The organic layer was separated, dried (magnesium sulphate) and filtered and the solvent evaporated under reduced pressure to afford a pale yellow oil. This was purified by flash chromatography on silica gel [ethyl acetate/petroleum ether (1:49)] to afford the title compound (Rf 0.25) as a colourless oil (1.97g, 85%). δH (300 MHz; CDCl3) 7.40-7.19 (5H, m, Ph), 5.94-5.74 (2H, m, CH2=CHCH and NCH2CH=CH2), 5.16-5.00 (4H, m, CH2=CHCH and NCH2CH=CH2), 4.02 (1H, q, J = 6.8, PhCHCH3), 3.90 (1H, app. q, J = 7.1, NCHCH2), 3.15 (2H, d, J = 6.1,
NCH2CH=CH2) , 2.41 (1H, dd, J = 6.4 and 14.5, CH2CO2), 2.31 (1H, dd, J = 14.5 and 8.3, CH2CO2), 1.42 (9H, s, (CH3)3C) , 1.39 (3H, d, J = 6.8, PhCHCH3) . Example 12
(2S,3S,αS)-t-Butyl 3-(N-allyl-α-methylbenzylamino)-2-hydroxy-3-phenylpropionate (27)
A solution of (S)-N-allyl-α-methylbenzylamine (2) (1.94g, 12.1 mmol) in anhydrous tetrahydrofuran (25 ml) was cooled to -78°C and 1.6M butyllithium (6.03 ml, 9.6 mmol) was added dropwise via a syringe. The resulting orange lithium amide solution was stirred at -78°C for 1 hour. A solution of t-butyl cinnamate (7) (1.64g, 8.1 mmol) in anhydrous tetrahydrofuran (15 ml) was then added via a cannula and the solution was stirred for a further 1 hour. The resulting yellow enolate solution was then diluted with anhydrous tetrahydrofuran (30 ml) and solid (+)-(camphorsulphonyl)-oxaziridine (2.76g, 12.1 mmol) was added. After stirring for a further 6 hours at -78°C, the mixture was warmed to 0°C (15 minutes) and quenched by the addition of saturated aqueous ammonium chloride solution. Ethyl acetate (50 ml) was added, followed by brine (10 ml). The organic layer was separated, dried (magnesium sulphate) and filtered and the solvent was evaporated under reduced pressure to afford an oily solid residue. Treatment of this with diethyl ether precipitated the oxaziridine/ sulfonimine which was removed by filtration and the resulting oil was purified by flash
chromatography on silica gel [ethyl acetate/petroleum ether (1:19)] affording the title compound (Rf 0.20) as a colourless oil (2.89g, 95%). δH (300 MHz: CDCl3) 7.50-7.21 (10H, m, Ph), 5.89 (1H, m, NCH2CH=CH2), 5.12 (1H, app. dd, J = 17.2 and 41.4, trans CH=CH2) , 5.04 (1H, app. dd, J = 17.2 and 1.4, cis CH=CH2), 4.53 (1H, d, J = 3.8, CHOH), 4.23 (1H, d, J = 3.8, NCHCH), 4.13 (1H, q, J = 6.8, PhCHCH3), 3.47 (1H, app. dd, J = 15.6 and 7.1, NCH2), 3.03 (1H, bs, OH), 1.29 (9H, s, (CH3)3CH), 1.21 (3H, d, J = 6.8, PhCHCH3). Example 13
(2S,3S,αS)-t-Butyl 3-(N-cinnamyl-α-methylbenzylamino)-2-hydroxy-3-phenylpropionate (28)
The procedure of Example 12 was repeated using (S)-N-cinnamyl-α-methylbenzylamine (4) (0.300g, 1.27 mmol), 1.6M butyllithium (0.730 ml, 1.17 mmol), t-butyl
cinnamate (7) (0.199g, 0.97 mmol) and (+)- (camphorsulphonyl)-oxaziridine (0.290g, 1.27 mmol).
Flash chromatography of the product on silica gel [ethyl acetate/petroleum ether (1:19)] afforded the title compound as a colourless oil (0.361g, 81%). δH (300 MHz; CDCl3) 7.55-7.12 (15H, m, Ph), 6.42 (1H, d, J = 16.0, PhCH=CH), 6.25 (1H, dt, J = 16.0 and 6.6, CH-CHPh), 4.61 (1H, d, J = 4.0, CHCHCO2) , 4.32 (1H, d, J = 4.0, PhCHCH), 4.20 (1H, q, J = 6.8, PhCHCH3), 3.65 (1H, dd, J = 15.8 and 5.7, NCH2), 3.47 (1H, dd, J = 15.8 and 6.9, NCH2), 3.22 (1H, br s, OH), 1.32 (9H, s, (CH3)3C), 1.29 (3H, d, J = 6.8, PhCHCH3).
De-allylation reactions
Standard procedure for de-allylation
A solution of the N-allylated β-amino ester (1.00 mmol) and tris(triphenylphosphine)rhodium(I) chloride (0.05 mmol) in acetonitrile/water (80:20, 50 ml) was prepared in a magnetically stirred 100 cm3 round bottomed flask. A Claisen adaptor fitted with an addition funnel on one arm and a short path distillation head and reflux condenser on the other was then attached to the reaction vessel. The addition funnel was charged with excess acetonitrile/ water (80:20) and the system was continually flushed with nitrogen as the reaction was brought to vigorous boiling, fresh solvent being added to replace the volume of liquid swept out of the distillation head. The reaction was refluxed for 2 hours and the solvent was then removed under reduced pressure. The dark brown oily residue was passed through alumina, eluting with diethyl ether, which after removal of solvent under reduced pressure afforded a pale yellow oil. This material was then subjected to flash chromatography on silica gel.
Example 14 (3S,αS)-t-Butyl 3-(α-methylbenzylamino)butanoate (29)
The title compound (29) was prepared from compound (6) of Example 1 using the above-described procedure. [α]D 21 - 36.3 (C 1.78, CHCl3); ʋma x(CHCl3) /cm-1 1724s (C=O); δH (300 MHz; CDCl3) 7.36-7.14 (5H, m, Ph), 3.89 (1H, q, J = 6.5, PhCHCH3), 2.94 (1H, m, CH3CHCH2), 2.34, 2.28 (2H, ABX system, JAB = 14.4, JAX = 5.6, JBX = 6.2, CH2CO), 1.45 (9H, s, (CH3)3C), 1.33 (3H, d, J = 6.6, PhCHCH3), 1.04 (3H, d, J = 6.5, CH3CHCH2); δc (50 MHz; CDCl3) 171.98 (C=O),
146.32 (Ph: Cipso), 128.60, 126.75 (Ph:Cortho, Cmeta), 127.03 (Ph:Cpara), 80.29 (C(CH3)3), 55.13, 47.98 (CHN), 41.86 (CH2CO), 28.03 (C(CH3)3), 24.46, 21.35 (NCHCH3) ; m/z (CD 264 (MH+, 100%), 208 (25), 148 (35), 105 (10) ; (Found: C, 72.93; H, 9.77; N, 5.10. C16H25NO2 requires C, 72.97; H, 9.57; N, 5.32%) .
Example 15
(3S,αS)-t-Butyl 3-(α-methylbenzylamino)-3-phenylpropionate (30)
The title compound (30) was prepared from compound (8) of Example 2 using the above -de scribed procedure. [α]D 21-16.3 (c 1.45, CHCl3) ; ʋmax (CHCl3) /cm-1 1728s (C=O); δH (300 MHz; CDCl3) 7.36-7.18 (10H, m, Ph), 4.17 (1H, dd, J =
7.9 and 6.2, NCHCH2), 3.67 (1H, q, J = 6.5, PhCHCH3), 2.65, 2.57 (2H, ABX system, JAB = 14.7, JAX = 7.9, JBX = 6.5, PhCHCH3) ; δc (50 MHz; CDCl3) 171.36 (C=O) , 146.38, 143.17 (Ph:Cipso) , 128.66, 127.33, 126.82 (Ph:Cortho, Cmeta), 127.46, 127.10 (Ph:Cpara), 80.51 (C(CH3)3), 57.15, 54.57 (CHN) , 43.94 (CH2CO), 27.97 (C(CH3)3), 22.29 (NCHCH3) ; m/z (Cl) 326 (MH+, 100%) , 270 (20) , 210 (30) , 120 (25) , 106
(28) ; (Found: C, 77.44; H, 8.59; N, 4.49. C21H27NO2 requires C, 77.50; H, 8.36; N, 4.30%) .
Example 16
(3S,αS)-t-Butyl 3-(α-methylbenzylamino)pentanoate (31)
The title compound (31) was prepared from compound (10) of Example 3 using the above-described procedure. [α]D 21 -54.0 (C 1.81, CHCl3) ; ʋmax(CHCl3) /Cm-1 1724s (C=O) ; δH (300 MHz; CDCl3) 7.36-7.20 (5H, m, Ph), 3.91 (1H, q, J = 6.5, PhCHCH3) , 2.68 (1H, m, NCHCH2), 2.39, 2.28 (2H, ABX system, JAB = 14.3, JAX = 5.7, JBX = 5.5, CH2CO) , 1.47 (9H, s, (CH3)3C) , 1.41 (2H, m, CH3CH2), 1.34 (3H, d, J = 6.5, PhCHCH3), 0.85 (3H, t, J = 7.3, CH3CH2) ; δc (50 MHz; CDCl3) 172.19 (C=O) , 146.44, (Ph:Cipso), 128.53, 126.92 (Ph:Cortho, Cmeta), 126.84 (Ph:Cpara), 80.23 (C(CH3)3) , 55.01, 53.71 (CHN), 39.10 (CH2CO) , 28.04 (C(CH3)3) , 27.78 (CH3CH2) , 24.80 (NCHCH3), 10.24 (CH3CH2) ; m/z (Cl) 278 (MH+, 100%) , 248 (5), 222 (30) , 192 (12), 162 (15) , 105 (20) ; (Found: C, 73.84; H, 10.11; N, 4.93. C17H27NO2 requires C, 73.61; H, 9.81; N, 5.05%) .
Example 17
(3R,αS)-t-Butyl 3-(α-methylbenzylamino)-4-hexenoate (32)
The title compound (32) was prepared from compound (12) of Example 4 using the above-described procedure. [α]D 21-45.1 (c 1.69, CHCl3); ʋmax(CHCl3) /cm-1 1728s (C=O); δH
(300 MHz; CDCI3) 7.32-7.18 (5H, m, Ph), 5.55 (1H, dq, J = 15.2 and 6.4, CH3CH=CH), 5.26 (ddq, J = 15.2, 8.0 and 1.6, CH3CH=CH), 3.84 (1H, q, J = 6.5, PhCHCH3), 3.45 (1H, m, NCHCH2) , 2.41, 2.35 (2H, ABX system, JAB = 14.5, JAX = 6.6, JBX = 6.5, CH2CO) , 1.65 (3H, dd, J = 6.4 and 1.6, CH3C=C) , 1.45 (9H, s, (CH3)3C), 1.33 (3H, d, J = 6.5, PhCHCH3) ; δc (50 MHz; CDCl3) 171.53 (C=O), 146.51 (Ph:Cipso) , 133.07
(CH3C=C) , 128.53, 126.82 (Ph:Cortho, Cmeta), 126.96
(Ph:Cpara) , 80.28 (C(CH3)3) , 55.14, 54.57 (CHN) , 41.78 (CH2CO) , 28.03 (C(CH3)3), 23.12 (NCHCH3) , 17.83 (CH3C=C) ; m/z (Cl) 290 (MH+, 100%), 234 (30), 174 (45), 105 (35); (Found: C, 74.61; H, 9.63; N, 4.62. C18H27NO2 requires C, 74.70; H, 9.40; N, 4.84%) .
Example 18 (3R,αS)-t-Butyl 3-(α-methylbenzylamino)-3-(fur-2-yl)propionate (33)
The title compound (33) was prepared from compound (14) of Example 5 using the above-described procedure. [α]D 21-1.5 (C 1.74, CHCl3) ; ʋmax (CHCl3) /cm-1 1729s (C=O) ; δH (300 MHz; CDCI3) 7.32-7.20 (6H, m, Ph, OCH=CH) , 6.28 (1H, dd, J = 3.2 and 1.9, OCH=CH), 6.15 (1H, d, J = 3.2, OCH=CH), 4.19 (1H, t, J = 6.9, NCHCH2) , 3.76 (1H, q, J = 6.5, PhCHCH3) ; δc (50 MHz; CDCl3) 170.93 (C=O) , 156.00 (OC=CH) , 146.15 (Ph:Cipso), 141.78 (OCH=CH), 128.61, 126.81
(Ph:Cortho, Cmeta), 127.14 (Ph:Cpara) , HO.10 (OCH=CH),
106.40 (OC=CH) , 80.55 (C(CH3)3) , 54.97, 50.83 (CHN) , 40.72 (CH2CO), 27.96 (C(CH3)3), 23.04 (NCHCH3) ; m/z (Cl) 316 (MH+, 100%) , 260 (25) , 200 (25) , 154 (20) , 120 (25), 105 (27) ; (Found: C, 72.37; H, 8.04; N, 4.31. C19H25NO3 requires C, 72.35; H, 7.99; N, 4.44%) . Example 19
(3R,αS)-t-Butyl 3-(α-methylbenzylamino)-4-methylpentanoate (34)
The title compound (34) was prepared from compound (16) of Example 6 using the above-de scribed procedure. [α]D 21-52.7 (c 1.57, CHCl3) ; ʋmax (CHCla) /cm-1 1724s (C=O) ; δH (300 MHz; CDCl3) 7.38-7.21 (5H, m, Ph) , 3.88 (1H, q, J = 6.5, PhCHCH3) , 2.60 (1H, m, NCHCH2) , 2.38, 2.27 (2H, ABX system, JAB = 14.4, JAB = 5.4, JBX = 6.2, CH2CO) , 1.68 (1H, m, (CH3)2CH), 1.47 (9H, s, (CH3)3C) , 1.33) (3H, d, J = 6.5, PhCHCH3) , 0.89 (3H, d, J = 6.8, (CH3)2CH) , 0.81 (3H, d, J = 6.8, (CH3)2CH) ; δc (50 MHz; CDCl3) 172.67 (C=O) , 146.58 (Ph:Cipso), 128.42, 127.12 (Ph:Cortho, Cmeta) , 126.95 (Ph:Cpara), 80.19 (C(CH3)3), 57.82, 55.37 (CHN) , 36.81 (CH2CO) , 31.14 ((CH3)2CH) , 28.03 (C(CH3)3) , 24.76 (NCHCH3) , 18.78, 18.32 ((CH3)2CH) ; m/z (Cl) 292 (MH+, 100%) , 236 (20), 192 (20), 176 (17), 105 (20); (Found: C, 74.07; H, 10.31; N, 4.58. C18H29NO2 requires C, 74.18; H, 10.03; N, 4.81%) .
Example 20 (3R,αS)-t-Butyl 3-(α-methylbenzylamino)-4-hexenoate (32)
To a solution of compound (12) from Example 4 1l.080g, 3.28 mmol) in anhydrous dichloromethane (20 ml) was added tetrakis-(triphenylphosphine)-palladium (0) (0.040g, 1 mol %) and N,N'-dimethylbarbituric acid (0.536, 9.85 mmol). This mixture was stirred at 40°C for 2 hours, after which the dichloromethane was removed under reduced pressure. The residue was dissolved in diethyl ether (50 ml) and washed with saturated sodium bicarbonate solution (2x20 ml) and brine (20 ml) and dried (magnesium
sulphate) and the solvent was removed under reduced pressure to yield a pale yellow oil. Purification by flash chromatography on silica gel [ethyl
acetate/petroleum ether (4:9)] afforded the title
compound (Rf 0.30) as a colourless oil (0.950g, 100%). δH (300 MHz; CDCl3) 7.32-7.18 (5H, m, Ph), 5.55 (1H, dq, J = 15.2 and 6.4, CH3CH=CH), 5.26 (1H, ddq, J = 15.2, 8.0 and 1.6, trans CH2CH=CH) , 3.84 (1H, q, J = 6.5, PhCHCH3), 3.45 (1H, m, NCHCH2), 2.41 (1H, dd, J = 14.5 and 6.6, CH2CO2), 2.35 (1H, dd, J = 14.5 and 6.5, CH2CO2), 1.65 (3H, dd, J = 6.4 and 1.6, CH3C=C), 1.45 (9H, s, (CH3)3C), 1.33 (3H, d, J = 6.5, PhCHCH3).
Transesterification reactions Example 21 (3S, αS)-Methyl-3-(α-methylbenzylamino)butanoate (35)
A solution of compound (29) from Example 14 (1.00 mmol) was stirred in a saturated solution of gaseous hydrogen chloride in methanol for 30 minutes. The solvent was then removed under reduced pressure. This procedure was repeated until no starting material remained. The white solid residue was diluted with ethyl acetate (30 ml), washed with saturated aqueous sodium bicarbonate (2 × 30 ml), water (20 ml) and brine (20 ml), dried (magnesium sulphate) and filtered, and the solvent was evaporated under reduced pressure to give the title compound (35) as a clear oil. [α]D 21 -45.5 (c 1.95, CHCl3); vmax(CHCl3) /cm-1 1736s (C=O); δH (300 MHz; CDCl3) 7.34-7.20 (5H, m, Ph), 3.88 (1H, q, J = 6.5, PhCHCH3) , 3.67 (3H, s, OCH3), 2.99 (1H, m, CH3CHCH2), 2.47, 2.38 (2H, ABX system, JAB = 14.8, JAX = 5.4, JBX = 6.5, CH2CO) , 1.33 (3H, d, J = 6.5
PhCHCH3), 1.06 (3H, d, J = 6.4, CH3CHCH2) ; δc (50 MHz;
CDCl3) 173.01 (C=O), 146.29 (Ph:Cipso), 128.63, 126.70 (Ph:Cortho, Cmeta), 127.07 (Ph:Cpara), 55.15, 47.69 (CHN), 51.30 (OCH3), 40.52 (CH2CO), 24.54, 21.34 (NCHCH3); m/z (CD 222 (MH+, 100%), 206 (15), 148 (10), 118 (5), 105 (10) ; (Found: C, 70.48; H, 8.80. C13H19NO2 requires C, 70.56; H, 8.65%) .
Example 22
(3R,αS)-Methyl 3-(α-methylbenzylamino)-3-phenylpropionate (36)
Following the procedure of Example 21 the title compound (36) was prepared from compound (30) of Example 15.
[α]D21 -14.9 (C 2.04, CHCl3) ; ʋmax (CHCla) /cm-1 1738s (C=O) ; δH (300 MHz; CDCl3) 7.36-7.21 (10H, m, Ph) , 4.23 (1H, dd, J = 6.2 and 7.7, NCHCH2) , 3.69 (1H, q, J = 6.5, PhCHCH3) , 3.64 (3H, s, OCH3), 2.78, 2.68 (2H, ABX system, JAB = 15.2, JAX = 7.7, JBX = 6.2, CH2CO) , 1.37 (3H, d, J = 6.5, PhCHCH3); δc (50 MHz; CDCl3) 172.51 (C=O), 146.25, 143.08 (Ph:Cipao), 128.81, 128.64, 127.61, 127.17, 126.81
(Ph:Cortho, Cmeta, Cpara) , 56.82, 54.64 (CHN) , 51.52 (OCH3) , 42.48 (CH2CO) , 22.26, (NCHCH3) ; m/z (Cl) 284 (MH+, 100%), 268 (13) , 236 (20), 210 (23), 106 (40) ; (Found: C, 76.06; H, 7.43; N, 4.84. C18H21NO2 requires C, 76.30; H, 7.47; N, 4.94%) .
Example 23
(3S,αS)-Methyl 3-(α-methylbenzylamino)pentanoate (37)
Following the procedure of Example 21 the title compound (37) was prepared from compound (31) of Example 16.
[α]D 21 -60.4 (c 1.77, CHCl3) ; ʋmax (CHCl3) /cm-1 1736s (C=O) ; δH (300 MHz; CDCl3) 7.36-7.18 (5H, m, Ph) , 3.89 (1H, q, J = 6.5, PhCHCH3), 3.67 (3H, s, OCH3), 2.73 (1H, m, NHCHCH2) 2.47, 2.39 (2H, ABX system, JAB = 14.7, JAB = 5.8, JBX =5.6, CH2CO), 1.41 (2H, m, CH3CH2) , 1.33 (3H, d, J = 6.6, PhCHCH3) , 0.86 (3H, t, J = 7.4, CH3CH2) ; δc (50 MHz ; CDCl3) 173.22 (C=O) , 146.29 (Ph:Cipao) , 128.55, 127.03, 126.86 (Ph:Cortho, Cmeta, Cpara) , 55.07, 53.44 (CHN) , 51.29 (OCH3) , 37.99 (CH2CO) , 27.89 (CH3CH2) , 24.80 (NCHCH3) , 10.20
(CH3CH2) ; m/z (CD 236 (MH+, 100%) , 220 (10) , 206 (15) , 105 (20) ; (Found: C, 71.08; H, 9.23; N, 5.81. C14H21NO2 requires C, 71.46; H, 8.99; N, 5.95%) .
Example 24
(3R,αS)-Methyl 3-(α-methylbenzylamino)-4-hexenoate (38) Following the procedure of Example 21 the title compouηfl
(38) was prepared from compound (32) of Example 17.
[α]D 21 -48.5 (c 1.28, CHCl3) ; ʋmax (CHCl3) /cm-1 1736s (C=O) , δH (300 MHz; CDCl3) 7.32-7.20 (5H, m, Ph) , 5.56 (1H, dq, J = 15.2 and 6.4, CH3CH=CH), 5.30 (1H, ddq, J = 15.2, 8.0 and 1.6, CH3CH=CH) , 3.84 (1H, q, J = 6.5, PhCHCH3), 3.67 (3H, s, OCH3) , 3.49 (1H, m,NCHCH2), 2.52, 2.46 (2H, ABX system, JAB = 18.9, JAX = 6.5, JBX = 6.5 CH2CO) , 1.65 (3H, dd, J = 6.4 and 1.6, CH3C=C), 1.32 (3H, d, J=6.5,
PhCHCH3) ; δc (50 MHz; CDCl3) 172.67 (C=0), 146.36
(Ph:Cipso) , 132.82 (CH3C=C) , 128.57, 126.79
(Ph:Cortho,Cmeta), 127.14 (Ph:Cpara), 54.76, 54.62 (CHN) , 51.36 (OCH3) , 40.34 (CH2CO), 23.12 (NCHCH3), 17.59
(CH3C=C) ; m/z (CD 248 (MH+, 100%) , 232 (10) , 174 (15), 105 (10) (Found: C, 72.89; H, 8.97. C15H21NO2 requires C, 72.84; H,8.50%) .
Example 25
(3R,αS)-Methyl 3-(α-methylbenzylamino)-3-(fur-2-yl)propionate (39)
Following the procedure of Example 21 the title compound
(39) was prepared from compound (33) of Example 18. ʋmax (CHCl3) /cm-1 1739s (C=O), δH (300 MHz; CDCl3) 7.32-7.18 (6H, m, Ph, OCH=CH), 6.29 (1H, dd, J = 3.3 and 1.9,
OCH=CH) , 6.15 (1H, d, J = 3.3, OCH=CH) , 4.25 (1H, t, J = 6.9, NCHCH2) , 3.76 (1H, q, J = 6.5, PhCHCH3), 3.67 (1H, s, OCH3) , 2.77 (2H, m, CH2CO) , 1.35 J = 6.5, PhCHCH3) ; δc (50 MHz; CDCl3) 172.12 (C=O) , 155.71 (OC=CH) , 146.00 (Ph:Cipso), 141.96 (OCH=CH), 128.64, 126.81 (Ph:Cortho, Cmeta), 127.21 (Ph:Cpara) , 110.18 (OCH=CH) , 106.48 (OC=CH) , 55.02, 51.58 (CHN) , 50.53 (OCH3) , 39.28 (CH2CO) , 22.98 (NCHCH3) ; m/z (CD 274 (MH+, 100%), 200 (20), 153 (20) ,
105 (25) (Found: C, 70.55; H, 7.03. C16H19NO3 requires C,
70.31; H,7.01%) . Example 26
(3R,αS)-Methyl 3-(α-methylbenzylamino)-4-methylpentanoate (40) Following the procedure of Example 21 the title compound (40) was prepared from compound (34) of Example 19.
[α]D 21 -57.5 (c 1.87, CHCl3) ; ʋmax (CHCl3) /cm-1 1736s
(C=O), δH (300 MHz; CDCl3) 7.36-7.21 (5H, m, Ph), 3.85 (1H, q, J = 6.5, PhCHCH3), 3.68 (3H, s, OCH3) , 2.66 (1H, m, NCHCH2) , 2.47, 2.37 (2H, ABX system, JAB = 14.6, JAX = 5.4, JBX = 6.5, CH2CO) , 1.67 (1H, m, (CH3)2CH) , 1.32 (3H, d, J = 6.5, PhCHCH3) ; 0.88 (3H, d, J = 6.8, (CH3) 2CH) , 0.81 (3H, d, J = 6.8, (CH3)2CH) ; δc (50 MHz; CDCl3) 173.73
(C=O) , 146.40 (Ph:Cipso) , 128.45, 127.06 (Ph:Cortho, Cmeta, Cpara), 57.52, 55.44 (CHN), 51.36 (OCH3), 35.75 (CH2CO),
31.31 [(CH3)2CH] , 24.74 (NCHCH3), 18.45, 18.36 [(CH3)2CH] ; m/z (Cl) 250 (MH+, 100%) , 236 (15), 206 (22) , 105 (22) ; (Found: C, 71.91; H, 9.67. C15H23NO2 requires C, 72.25;
H, 9.30%) .
Cyclisation and other transformations
Example 27
(4S,αS)-1-(α-Methylbenzyl)-4-methylazetidin-2-one (41)
To a solution compound (35) from Example 21 (1.00 mmol) in anhydrous diethyl ether (5 ml) at 0°C was added slowly, dropwise, 3.0 M methylmagnesium bromide (1.10 mmol). The resulting solution was stirred for 10 minutes and the reaction was then quenched by addition of pH7 buffer.
Diethyl ether (20 ml) was added, whereafter the solution was washed with water (20 ml) and brine (20 ml), dried (magnesium sulphate) and filtered. The solvent was removed under reduced pressure to afford the title
compound (41) as a clear oil which was subjected to flash chromatography on silica gel. [α]D 21 -68.9 (c 1.61,
CHCl3) ; ʋmax (CHCl3)/cm-1 1742s (C=O), δH (300 MHz; CDCl3) 7.34-7.23 (5H, m, Ph), 4.92 (1H, q, J = 7.2, PhCHCH3), 3.51 (1H, m, CH3CHCH2); 2.97, 2.46 (2H, ABX system, JAB = 14.4, JAX = 5.1, JBX = 2.4, CH2CO), 1.63 (3H, d, J = 7.2,
PhCHCH3), 1.25 (3H, d, J = 6.1, CH3CHCH2); δc (50 MHz;
CDCl3) 166.90 (C=O), 140.67 (Ph:Cipso), 128.85, 127.18 (Ph:Cortho,Cmeta), 127.77 (Ph: Cpara), 51.78, 47.18 (CHN) , 43.45(CH2CO), 20.65, 19.25 (NCHCH3); m/z (Cl) 190 (MH+, 100%), 174(5), 132 (10), 105 (8); (Found: C, 76.02; H, 7.98; 7.07. C12H15NO requires C, 76.16; H, 7.99; N,
7.40%).
Example 28 (4R,αS)-_1-(α-Methylbenzyl)-4-phenylazetidin-2-one (42)
Following the procedure of Example 27 the title compound
(42) was prepared from compound (36) of Example 22.
[α]D 21 +57.9 (c 1.06, CHCl3) ; ʋmax (CHCl3) /cm-1 1747s (C=O) ; δH (300 MHz; CDCl3) 7.34-7.18 (10H, m, Ph), 5.05
(1H, q, J = 7.2, PhCHCH3) , 4.30 (1H, dd, J = 5.3 and 2.5, NCHCH2) , 3.25, 2.84 (2H, ABX system, JAB = 14.7, JAX = 5.3, JBX = 2.5, CH2CO) , 0.87 (3H, d, J = 7.2, PhCHCH3) ; δc
(50MHz; CDCl3) 167.66 (C=O), 140.18, 139.99 (Ph:Cipso) , 128.93, 128.82, 127.48, 126.89 (Ph:Cortho, Cmeta) , 128.63, 128.19 (Ph: Cpara) , 53.40 (CHN) , 46.28 (CH2CO) , 18.67
(NCHCH3) ; m/z (Cl) 252 (MH+, 100%) , 236 (4) 132 (10) , 104 (60); (Found: C, 81.11 H, 6.96. C11H17NO requires C,
81.24; H, 6.82%).
Example 29
(4S,αS)-1-(α-Methylbenzyl)-4-ethylazetidin-2-one (43)
Following the procedure of Example 27 the title compound
(43) was prepared from compound (37) of Example 23.
[α]D 21 -8.9 (C 1.84, CHCl3) ; ʋmax (CHCl3) /cm-1 1742s (C=O) ; δH (300 MHz; CDCI3) 7.38-7.25 (5H, m, Ph) , 4.88
(1H, q, J = 7.2, PhCHCH3), 3.34 (1H, m, NCHCH2) , 2.88, 2.48 (2H, ABX system, JAB = 14.5, JAX = 5.1, JBX = 2.4, CH2CO) , 1.75 (1H, m, CH3CH2), 1-62 (3H, d, J = 7.2,
PhCHCH3) , 1.38 (1H, m, CH3CH2), 0.80 (3H, t, J = 7.4,
CH3CH2) ; δc (50 MHz; CDCl3) 167.13 (C=O) , 140.85 (Ph:Cipso) , 128.81, 127.11 (Ph:Cortho, Cmeta), 127.69 (Ph: Cpara) , 52.72, 52.05 (CHN) , 40.92 (CH2CO), 27.07 CH3CH2) , 19.48 (NCHCH3), 9.11 (CH3CH2) ; m/z (Cl) 204 (MH+, 100%) , 188 (5) , 146 (6), 105 (10) ; (Found: C, 76.65; H, 8.67. C13H17NO requires C, 76.81; H, 8.43%) .
Example 30 (4R,αS)-1-(rγ-Methylbenzyl)-4-propenylazetidin-2-one (44)
Following the procedure of Example 27 the title compound
(44) was prepared from compound (38) of Example 24.
[α]D 21 -39.4 (c 1.02, CHCl3); δH (300 MHz ; CDCl3) 7.38-7.25 (5H, m, Ph), 5.61 (1H, dq, J = 15.2 and 6.4,
CH3CH=CH), 5.38 (1H, ddq, J = 15.2, 8.0 and 1.6,
CH3CH=CH), 4.92 (1H, q, J = 7.2, PhCHCH3), 3.81 (1H, m, NCHCH2), 2.99, 2.57 (2H, ABX system, JAB = 14.6, JAX = 5.2, JBX = 2.2, CH2CO), 1.67 (3H, dd, J = 6.4 and 1.6, CH3C=C), 1.54 (3H, dd, J = 7.2, PhCHCH3). Example 31
(4R.KS)-1-(α-Metbylheπzvl)-4-(fur-2-yl)-azetidin-2-one (45)
Following the procedure of Example 27 the title compound
(45) was prepared from compound (39) of Example 25.
[α]D 21 +36.7 (C 1.96, CHCl3) ; ʋmax(CHCl3)/cm-1 1751s (C=O) ; δH (300 MHz; CDCl3) 7.39-7.23 (6H, m, Ph, OCH=CH) , 6.33 (1H, dd, J = 3.3 and 1.9, OCH=CH), 6.21 (1H, d, J = 3.3, OCH=CH) , 5.00 (1H, q, J = 7.2, PhCHCH3), 4.38 (1H, m, NCHCH2) , 3.14 (2H, m, CH2CO) , 1.30 (3H, d, J = 7.2,
PhCHCH3) ; δc (50 MHz; CDCl3) 166.60 (C=O) , 151.53 (OC=CH) , 142.82 (Ph:Cipso) , 139.91 (OCH=CH), 128.72, 127.24
(Ph:Cortho, Cmeta), 121.74 (Ph:Cpara), 110.69 (OCH=CH),
109.09 (OC=CH) , 51.42, 45.97 (CHN), 42.44 (CH2CO) , 17.60 (NCHCH3) ; m/z (CI) 242 (MH+, 100%), 226 (4), 132 (8), 94 (40) ; Found: C, 74.45; H, 6.45. C15H15NO2 requires C, 74.67; H, 6.27%) .
Example 32
(4R,αS)-1-(α-Methylbenzvl)-4-isopropvlazetidin-2-one (46) Following the procedure of Example 27 the title compound
(46) was prepared from compound (40) of Example 26.
[α]D 21 +26.1 (C 1.96, CHCl3) ; ʋmax (CHCLj) /cm-1 1741s (C=O) , δH (300 MHz; CDCl3) 7.38-7.25 (5H, m, Ph) , 4.83
(1H, q, J = 7.2, PhCHCH3) , 3.36 (1H, m, NCHCH2) , 2.72, 2.57 (2H, ABX system, JAB = 14.7, JAX = 5.2, JBX = 2.7, CH2CO) , 1.88 (1H, m, (CH3)2CH) , 1.65 (3H, d, J = 7.2, PhCHCH3) , 0.83 (3H, d, J = 6.8, (CH3)2CH) , 0.79 (3H, d, J = 6.8, (CH3)CH) ; δc (50MHz; CDCl3) 167.73 (C=O) , 141.09 (Ph:Cipso) , 128.78, 127.14 (Ph:Cortho, Cmeta) , 127.62 (Ph: Cpara) , 56.72, 52.95 (CHN) , 36.59 (CH2CO) , 29.16
((CH3)2CH), 19.30, 18.83, 14.91 (NCHCH3, (CH3)2CH) ; m/z (CD 218 (MH+, 100%) , 202 (10) , 132 (10) , 105 (15) ; ( Found : C, 77 . 47 ; H, 8 . 96 . C14H19NO requires C, 77 . 38 ; H, 8 . 81% ) .
Example 33
(2S,4S,5S,αS)-2-Ethyl-3-(α-methylbenzyl)-4-Phenyl-1,3-oxazolidine-5-carboxylic acid t-butyl ester (47)
To a solution of compound (27) from Example 12 (1.039g, 2.73 mmol) in anhydrous toluene (25 ml) was added
tris (triphenylphosphine) rhodium(I) chloride (126 mg, 5 mol %). This solution was refluxed for 4 hours
whereafter the toluene was removed under reduced
pressure. The residue was treated with diethyl ether, precipitating the catalyst, and the solution was passed through alumina grade 5. After removal of the solvent under reduced pressure, the resulting oil was purified by flash chromatography on silica gel [ethyl acetate/ petroleum ether (1:19)] affording the title compound (Rf 0.40) as a colourless oil (0.86g, 83%). δH (300 MHz;
CDCl3) 7.33-7.18 (10H, m, Ph), 4.48 (1H, t, NCHO), 4.38 (1H, d, J = 8.0, PhCHCH), 4.21 (1H, d, J = 8.0, PhCHCH), 4.01 (1H, q, J = 6.9, PhCHCH3), 1.91 (2H, m, CHCH2CH3), 1.27 (3H, d, J = 6.9, PhCHCH3), 1.15 (3H, t, J = 7.5, CHCH2CH3), 0.99 (9H, s, (CH3)3C).
Example 34
(2S,3S,6R,αS)-3-Phenyl-4-(«-mettιylbenzyl)-6-ioflomethyl-1.4-oxazine-2-carboxylic acid t-butyl ester (48)
To a solution of compound (27) from Example 12 (250 mg, 0.66 mmol) in tetrahydrofuran/water (9:1, 3 ml) at 0°C was added N-iodosuccinimide (295 mg, 1.32 mmol). This solution was stirred at 0°C for 2 hours. The resulting brown solution was poured into 1.0M aqueous sodium
thiosulphate solution (20 ml) and this was washed with brine (20 ml), dried (magnesium sulphate) and filtered and the solvent was removed under reduced pressure to give a yellow oil. This was purified by flash
chromatography on silica gel [ethyl acetate/petroleum ether (1:19)] to give the title compound (48) (Rf 0.20) as a colourless oil (160 mg, 48%). δH (300 MHz; CDCl3) 7.61-7.22 (10H, m, Ph), 4.65 (1H, d, J = 3.7, CHCO2), 4.36 (1H, d, J = 3.7, NCHCH), 3.75-3.66 (1H, m, CHCH2I), 3.33 (1H, q, J = 6.4, PhCHCH3), 3.31 (1H, dd, J = 10.4 and 5.0, CH2I), 3.24 (1H, dd, J = 10.4 and 6.2, CH2I), 2.58 (1H, dd, J = 12.6 and 3.3, eq. NCH2CH), 1.49 (3H, d, J = 6.4, PhCHCH3), 1.14 (9H, s, (CH3)3C).
Also recovered (Rf 0.45) as a colourless oil was the corresponding (2S,3S,6S,αS) isomer (40 mg, 12%). δH (300 MHz; CDCl3) 7.56-7.21 (10H, m, Ph), 4.60 (1H, d, J = 4.6, CHCO2) , 4.47-4.39 (1H, m, CHCH2I), 4.29 (1H, d, J = 4.6, PhCHCH), 3.65 (1H, q, J = 6.5, PhCHCH3), 3.50 (1H, dd, J = 10.0 and 7.1, CH2I), 3.37 (1H, dd, J = 10.0 and 5.5,
CH2I), 2.45 (1H, dd, J = 12.3 and 5.4, ax. NCH2CH), 1.38 (3H, d, J = 6.5, PhCHCH3), 1-18 (9H, s, (CH3)3C).
Example 35 (3R,2S,3'R,αR)-t-Butyl-2-hydroxyethyl-3-(N-allyl-α-methylbenzylamino)-4-pentenoate (49)
A solution of diisopropylamine (0.930 ml, 6.6 mmol) in anhydrous tetrahydrofuran (10 ml) was cooled to -78°C prior to the dropwise addition of 1.6M butyllithium (3.54 ml, 5.7 mmol) via a syringe. The solution was warmed to 0°C and stirred for 15 minutes. A solution of compound (26) from Example 11 (0.595g, 1.9 mmol) in
tetrahydrofuran (20.ml) was then added dropwise via a cannula and the solution was stirred at 0°C for a further 2 hours. The reaction mixture was then cooled to -78°C and trimethyl borate (0.539 ml, 5.7 mmol) was added dropwise via a syringe and the solution was stirred for 15 minutes. Acetaldehyde (1.10 ml, 19.9 mmol) was then added and the solution was stirred for 30 minutes before quenching the reaction with saturated aqueous ammonium chloride solution. Ethyl acetate (50 ml) was added, followed by brine (10 ml). The organic layer was
separated, dried (magnesium sulphate) and filtered and the solvent was evaporated under reduced pressure to afford a yellow oil. This was purified by flash
chromatography on silica gel [ethyl acetate/petroleum ether (1:9)] affording the title compound (49) (Rf 0.25) as a colourless oil (0.332g, 49%) and a mixture of the title compound and the second major diastereoisomer as a colourless oil (0.20g, 30%). δH (300 MHz; CDCl3) 7.37-7.20 (5H, m, Ph), 6.10 (1H, dt, J = 17.1 and 10.1,
CH2=CHCH) , 5 . 76 (1H, m, CH2CH=CH2) , 5 .30 (1H, dd, J = 10 .2 and 1 . 7 , cis CH2CH=CH2) , 5 .20 (1H, dd, J = 17 .1 and 1. 7 , trans CH2CH=CH2) , 5 . 00 (2H, m, CH2=CHCH) , 4 .78 (1H, br s ,
OH) , 4 .21 (1H, q, J = 6 . 8 , PhCHCH3) , 4 . 10 (1H, dq, J = 8 .5 and 6.1, CH3CHOH), 3.78 (1H, dd, J = 10.1 and 6.8, NCHCH), 3.27 (1H, dd, J = 15.4 and 5.9, NCH2), 3.13 (1H, dd, J = 15.4 and 7.3, NCH2), 2.86 (1H, dd, J = 8.5 and 6.8,
CHCO2), 1.45 (9H, S, (CH3)3C), 1.36 (3H, d, J = 6.8,
PhCHCH3), 1.19 (3H, d, J = 6.1, CH3CHOH) .
Example 36
(2S,4R,5S,6R,αR)-2-Ethyl-3-(α-methylbenzyl)-4-viny1-6-methyl-1.3-oxazine-5-carboxylic acid t-butyl ester (50)
Compound (49) from Example 35 (0.246g, 0.69 mmol) was treated with tris (triphenylphosphine) rhodium(I) chloride
(0.032g, 0.034 mmol) in accordance with the procedure of Example 33. Flash chromatography of the product on silica gel [ethyl acetate/petroleum ether (1:19)]
afforded the title compound (Rf 0.40) as a colour-less oil
(0.182g, 74%). δH (300 MHz; CDCl3) 7.51-7.23 (5H, m, Ph), 5.94 (1H, ddd, J = 16.9, 10.3 and 5.4, CH2=CHCH), 5.36 (1H, app. dt. J = 16.9 and 2.1, trans CH2CH), 5.20 (1H, app. dt, J = 10.3 and 2.1, cis CH2=CH), 4.55 (1H, q,
PhCHCH3) , 4.39 (1H, app. t, J = 6.5, NCHO) , 3.87 (1H, app. tt, J = 5.8 and 1.9, CH2=CHCH), 3.68 (1H, dq, J = 10.9 and 5.9, CHCH3O), 2.00-1.89 (1H, m, CH2CH3), 1.34 (9H, s, (CH3)3C) , 1.30 (1H, m, J = 6.8, CH2CH3), 1.13 (1H, dd, J = 10.9 and 6.1, CHCO2), 1.03 (3H, t, J = 7.4, CHCH2CH3), 0.89 (3H, d, J = 5.9, CHCH3O) .
Example 37
(2S,3R,αS)-t-Butyl 2-methyl-3-(N-allyl-α-methylbenzylamino)-3-phenylpropanoate (51)
A solution of diisopropylamine (0.691 ml, 4.93 mmol) in anhydrous tetrahydrofuran (10 ml) was cooled to -78°C prior to the dropwise addition of 1.6M butyllithium (2.57 ml, 4.11 mmol) via a syringe. The solution was warmed to 0°C and then immediately recooled to -78°C, whereupon a solution of compound (8) from Example 2 (600 mg, 1.64 mmol) in tetrahydrofuran (10 ml) was added dropwise via a cannula. Stirring was continued for 1 hour at -78°C followed by the rapid injection of methyl iodide (0.512 ml, 8.22 mmol) . The reaction mixture was allowed to warm slowly to room temperature overnight (16 hours) after which the solvent was evaporated. The residue was partitioned between ethyl acetate (50 ml) and brine (25 ml) and the organic layer was dried (magnesium sulphate), filtered and evaporated to yield a yellow oil. This was purified by flash chromatography on silica gel [ethyl acetate/petroleum ether (1:49)] affording the title compound (51) in 94% diastereoisomeric excess (Rf 0.25) as a colourless oil (406 mg, 65%). δH (300 MHz; CDCl3) 7.41-7.17 (10H, m, Ph), 5.93-5.79 (1H, m, NCH2CH=CH2), 5.11 (1H, app. dd, J = 17.3 and 1.3, trans CH=CH2), 5.08 (1H, app. dd, J = 10.1 and 1.1, cis CH=CH2), 4.18 (1H, d, J = 11.4, PhCHCH3), 3.29 (1H, app. ddt, J = 14.7, 5.0 and 1.9, NCH2) , 3.19 (1H, dq, J = 11.4 and 6.9, CHCHCH3), 3.10 (1H, dd, J = 14.7 and 8.0, NCH2), 1.50 (9H, s, (CH3)3C), 0.94 (3H, d, J = 6.7, PhCHCH3), 0.90 (3H, d, J = 6.9, CHCHCH3) .
Example 38
(2S,2R,3'S,αS)-t-Butyl 2-hydroxvethyl-3-(N-allyl-α-methylbenzylamino)-4-hexenoate (52)
Compound (12) from Example 4 (0.2g, 0.61 mmole) was treated in accordance with the procedure of Example 35, using diisopropylamine (0.298 ml, 2.13 mmol), 1.6M
butyllithium (1.140 ml, 1.82 mmol), trimethyl borate
(0.207 ml, 1.82mmol) and acetaldehyde (0.340 ml, 6.08 mmol). Flash chromatography on silica gel [ethyl
acetate/petroleum ether (1:9)] afforded the title
compound (52) and the second major diastereoisomer (Rf 0.30) as a colourless oil (0.173g, 76%). δH (500 MHz;
CDCI3) 7.38-7.20 (5H, m, Ph), 5.80-5.70 (2H, m, NCH2CH=CH2 and CH3CH=CH), 5.60 (1H, dq, J = 15.3 and 6.3, CH3CH=CH), 5.00 (2H, m, NCH2CH=CH2), 4.22 (1H, q, J = 6.8, PhCHCH3), 4.12 (1H, dq, J = 6.1 and 8.8, CH3CHOH), 3.75 (1H, dd, J = 10.0 and 6.3, NCHCH), 3.25 (1H, dd, J = 15.4 and 6.0, NCH2), 2.81 (1H, dd, J = 8.8 and 6.3, CH2CO2) , 1.74 (3H, dd, J = 6.3 and 1.4, CH3CH=CH), 1.44 (9H, s, (CH3)3C), 1.35 (3H, d, J = 6.7, PhCHCH3), 1.18 (3H, d, J = 6.1, CH3CHOH) . Example 39
(3S , 2R , 3 ' R , αS ) -t-Butyl 2 -hydroxvethyl-3 - (N-allyl-α-methylbenzyl amino) -5 -phenvl-4-pentenoate ( 53 ) Compound ( 20 ) from Example 8 ( 0 .250g, 0 .64 mmol) was treated in accordance with the procedure of Example 35 , using diisopropylamine ( 0 .314 ml , 2 .24 mmol) , 1.6M butyllithium (1.20 ml, 1.92 mmol) and acetaldehyde (0.36 ml, 6.40 mmol). Flash chromatography on silica gel
[ethyl acetate/petroleum ether (1:9)] afforded the title compound (53) and the second major diastereoisomer (Rf 0.30) as a colourless oil (0.206g, 74%). δH (300 MHz; CDCl3) 7.41-7.22 (10H, m, Ph), 6.49 (1H, d, J = 16.0, PhCH=CH), 6.24 (1H, dd, J = 16.0 and 9.4, PhCH=CHCH), 5.91-5.76 (1H, m, NCH2CH=CH2), 5.18-5.02 (2H, m,
NCH2CH=CH2), 4.31 (1H, q, J = 6.8 and 1.5, PhCHCH3), 4.19 (1H, dq, J = 8.3 and 6.2, CH3CHOH), 3.98 (1H, app. dt, J 7.2 and 1.9, NCHCH), 3.34-319 (2H, m, NCH2CH=CH2), 2.98 (1H, dd, J = 8.3 and 6.9, CH2CO2), 1.44 (9H, s, (CH3)3C), 1.42 (3H, d, J = 6.8, PhCHCH3), 1.24 (3H, d, J = 6.2, CH3CHOH).
Example 40
(2S,3S,αS)-t-Butyl 3-(N-cinnamoyl-α-methylbenzylaminn)-2-hydroxy-3-phenylpropionate (54)
Compound (28) from Example 13 (0.200g, 0.44 mmol) was treated with N-iodosuccinimide (0.197g, 0.88 mol) using standard iodoetherification conditions. Flash
chromatography of the product on silica gel [ethyl acetate/petroleum ether (1:9)] afforded the title
compound (54) (Rf 0.50) as a yellow oil (0.093g, 45%). δH (200 MHz; CDCl3) 7.72 (1H, d, J = 16.0, CH=CHPh), 7.57-7.22 (15H, m, Ph), 6.51 (1H, d, J = 16.0, PhCH=CH), 5.45 (1H, d, J = 4.9, CHCHOH), 4.25 (1H, d, J = 4.9, PhCHCH), 3.81 (1H, q, J = 6.5, PhCHCH3), 1.92 (1H, br S, OH), 1.34 (3H, d, J = 6.5, PhCHCH3), 1.32 (9H, s, (CH3)3C). The corresponding 3-(α-methylbenzylamino) derivative (Rf 0.25) was also recovered as a colourless oil (0.045g, 30%). δH (200 MHz; CDCl3) 7.48-7.14 (10H, m, Ph), 4.50 (1H, d, J = 3.8, CHCHOH), 4.09 (1H, d, J = 3.8, PhCHCH), 3.76 (1H, q, J = 6.6, PhCHCH3) , 1.38 (3H, d, J = 6.6, PhCHCH3), 1.31 (9H, s, (CH3)3C).

Claims

1. Compounds of general formula (I)
Figure imgf000044_0001
(wherein R represents a carbocyclic aryl group, R1 represents an organic group, R2 represents a hydrogen atom or an organic group, and the asterisk denotes that the group R1 is predominantly in the R- or S- configuration such that the compound is in substantially
enantiomerically pure form) .
2. Compounds as claimed in claim 1 comprising at least 95% of a single enantiomer.
3. Compounds as claimed in claim 1 or claim 2 wherein R represents phenyl or naphthyl optionally substituted by one or more of halo, hydroxy, lower alkoxy, lower
alkylthio, lower alkylsulphonyl, amino, substituted amino, carboxy, cyano, lower alkoxycarbonyl,
carbamoyloxy, sulphamoyl and sulphoxy.
4. Compounds as claimed in claim 3 wherein R is
selected from phenyl and 3,4-dimethoxyphenyl.
5. Compounds as claimed in any of the preceding claims wherein R1 is selected from optionally substituted C1-10 alkyl, C2-10 alkenyl, C3-10 cycloalkyl, C3-10 cycloalkyl-C1-4 alkyl and C6-12 aryl-C1-4 alkyl groups.
6. Compounds as claimed in claim 5 wherein R1 represents a methyl group.
7. Compounds as claimed in any of the preceding claims wherein R2 represents a C1-10 alkyl, C2-10 alkenyl or C6-20 carbocyclic aryl group or a heterocyclic group.
8. Compounds as claimed in any of claims 1 to 6 wherein R2 represents a hydrogen atom or a phenyl group.
9. The lithium amides of (S)-N-allyl-α-methylbenzylamine; (S)-(E,E)-N-hexa-2,4-dienyl-α-methylbenzylamine; and (S)-N-cinnamyl-α-methylbenzylamine.
10. Solutions of compounds as claimed in any of the previous claims.
11. A process for the preparation of a compound of general formula (I) as defined in claim 1 which comprises reacting a compound of general formula (V)
Figure imgf000045_0001
(where R, R1, R2 and the meaning of the asterisk are as defined in claim 1) with a lithium alkyl.
12. Use of a compound of general formula (I) as defined in any of claims 1 to 10 in stereoselective syntheses .
13. Use as claimed in claim 12 wherein the compound of general formula (I) undergoes stereoselective Michael addition to an α,β-unsaturated carboxylic acid
derivative.
14. Use as claimed in claim 12 wherein the product of the Michael addition is subjected to cleavage of the allylic N-substituent R2.CH:CH.CH2- and cyclisation to form a β-lactam.
PCT/GB1994/002827 1993-05-19 1994-12-28 Improvements in or relating to chiral syntheses WO1995018134A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP6517861A JP2964639B2 (en) 1993-05-19 1993-12-24 Mixed fiber composite false twist yarn, method for producing the same, and knitted fabric using the yarn
DK95904629T DK0736031T3 (en) 1993-12-24 1994-12-28 Improvements in chiral synthesis
EP95904629A EP0736031B1 (en) 1993-12-24 1994-12-28 Improvements in or relating to chiral syntheses
AT95904629T ATE192449T1 (en) 1993-12-24 1994-12-28 IMPROVEMENTS IN CHIRAL SYNTHESIS
US08/663,257 US6037498A (en) 1993-12-24 1994-12-28 Chiral syntheses
DE69424313T DE69424313T2 (en) 1993-12-24 1994-12-28 IMPROVEMENTS IN CHIRAL SYNTHESIS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9326403.4 1993-12-24
GB939326403A GB9326403D0 (en) 1993-12-24 1993-12-24 Improvements in or relating to chiral syntheses

Publications (1)

Publication Number Publication Date
WO1995018134A1 true WO1995018134A1 (en) 1995-07-06

Family

ID=10747180

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1994/002827 WO1995018134A1 (en) 1993-05-19 1994-12-28 Improvements in or relating to chiral syntheses

Country Status (9)

Country Link
US (1) US6037498A (en)
EP (1) EP0736031B1 (en)
JP (1) JP2964639B2 (en)
AT (1) ATE192449T1 (en)
DE (1) DE69424313T2 (en)
DK (1) DK0736031T3 (en)
ES (1) ES2145260T3 (en)
GB (1) GB9326403D0 (en)
WO (1) WO1995018134A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012697A2 (en) * 1994-10-21 1996-05-02 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5981599A (en) * 1996-05-01 1999-11-09 Nps Pharmaceuticals, Inc. Inorganic ion receptor active compounds
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6057346A (en) * 1994-12-12 2000-05-02 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of retroviral LTR promoters by calcium response modifiers
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
EP1258471A2 (en) * 1996-05-01 2002-11-20 Nps Pharmaceuticals, Inc. Inorganic ion receptor-active compounds
WO2003085120A1 (en) * 2002-04-08 2003-10-16 Ube Industries, Ltd. PROCESS FOR PRODUCING EITHER OPTICALLY ACTIVE N-SUBSTITUTED ß-AMINO ACID AND OPTICALLY ACTIVE N-SUBSTITUTED ß-AMINO ACID ESTER OR OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID AND OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID ESTER
EP1770083A1 (en) * 1996-05-01 2007-04-04 Nps Pharmaceuticals, Inc. Inorganic ion receptor-active compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0697015A1 (en) * 1993-05-06 1996-02-21 PHARMACIA & UPJOHN COMPANY Optically active 3-(1-(alkylamino))alkyl pyrrolidines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
G. CARDILLO ET. AL.: "A new approach to the synthesis of enantiomerically pure 2,3-diaminoacids through chiral imidazolidin-2-ones.", TETRAHEDRON, (INCL. TETRAHEDRON REPORTS), vol. 47, no. 12, 25 March 1991 (1991-03-25), OXFORD GB, pages 2263 - 72 *
P. D. BAILEY ET. AL.: "Asymmetric 3-aza-Cope Rearrangements using TiCl4 Catalysis.", TETRAHEDRON LETTERS., vol. 30, no. 39, 1989, OXFORD GB, pages 5341 - 4 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6211244B1 (en) 1994-10-21 2001-04-03 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
EP1275635A1 (en) * 1994-10-21 2003-01-15 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
WO1996012697A2 (en) * 1994-10-21 1996-05-02 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
WO1996012697A3 (en) * 1994-10-21 1996-06-13 Nps Pharma Inc Calcium receptor-active compounds
EP1203761A2 (en) * 1994-10-21 2002-05-08 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
EP1203761A3 (en) * 1994-10-21 2002-05-15 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
EP1553078A1 (en) * 1994-10-21 2005-07-13 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
US6057346A (en) * 1994-12-12 2000-05-02 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of retroviral LTR promoters by calcium response modifiers
EP1258471A2 (en) * 1996-05-01 2002-11-20 Nps Pharmaceuticals, Inc. Inorganic ion receptor-active compounds
EP1258471A3 (en) * 1996-05-01 2002-12-11 Nps Pharmaceuticals, Inc. Inorganic ion receptor-active compounds
US5981599A (en) * 1996-05-01 1999-11-09 Nps Pharmaceuticals, Inc. Inorganic ion receptor active compounds
EP1770083A1 (en) * 1996-05-01 2007-04-04 Nps Pharmaceuticals, Inc. Inorganic ion receptor-active compounds
WO2003085120A1 (en) * 2002-04-08 2003-10-16 Ube Industries, Ltd. PROCESS FOR PRODUCING EITHER OPTICALLY ACTIVE N-SUBSTITUTED ß-AMINO ACID AND OPTICALLY ACTIVE N-SUBSTITUTED ß-AMINO ACID ESTER OR OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID AND OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID ESTER
US7449325B2 (en) 2002-04-08 2008-11-11 Ube Industries, Ltd. Process for enzymatically producing either optically active N-substituted β-amino acids or esters thereof or optically active N-substituted 2-homopipecolic acids or esters thereof

Also Published As

Publication number Publication date
EP0736031B1 (en) 2000-05-03
DK0736031T3 (en) 2000-09-04
GB9326403D0 (en) 1994-02-23
DE69424313T2 (en) 2000-08-24
JP2964639B2 (en) 1999-10-18
ATE192449T1 (en) 2000-05-15
EP0736031A1 (en) 1996-10-09
JPH09507221A (en) 1997-07-22
ES2145260T3 (en) 2000-07-01
US6037498A (en) 2000-03-14
DE69424313D1 (en) 2000-06-08

Similar Documents

Publication Publication Date Title
EP0736031B1 (en) Improvements in or relating to chiral syntheses
Bourzat et al. A practical access to chiral phenylisoserinates, preparation of Taxotere® analogs
AU703927B2 (en) 7-amino-2-heptenoates and their use in the preparation of methylphenidate
CA2432064A1 (en) Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
US5929284A (en) Processes for producing α-halo ketones, α-halohydrins and epoxides
MXPA98007879A (en) 7-amino-2-heptenoatos and its use in the preparation of metilfenid
Gennari et al. Highly enantio-and diastereoselective boron aldol reactions of α-heterosubstituted thioacetates with aldehydes and silyl imines
CN1020604C (en) Process for preparation of (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
US4751299A (en) Optically active β-lactams and method of their production
Bravo et al. Enantiomerically Pure (z-Fluoroalkyl-ct-Amino Acids: Synthesis of (R)-(x-Difluoromethyl-Alanine and (S)-(x-DifluoromethyI-Serine
JPH0757752B2 (en) Antibiotic intermediates
Madau et al. Stereoselective synthesis of unnatural aminoacids cis-4-hydroxyproline and bulgecinine
Skrinjar et al. An efficient synthesis of (+)-anatoxin-a.
US5668164A (en) Process for synthesis of chiral cis-and trans-3-amino-4 substituted pyrrolidine compounds
Pyne et al. Diastereoselective addition of α-hydroxyalkyl and α-alkoxyalkyl radicals to chiral 4-methyleneoxazolidin-5-ones
Tanaka et al. Asymmetric syntheses of all four isomers of 4-amino-4-carboxyproline: Novel conformationally restricted glutamic acid analogues
Gessier et al. Preparation of β2‐Amino Acid Derivatives (β2hThr, β2hTrp, β2hMet, β2hPro, β2hLys, Pyrrolidine‐3‐carboxylic Acid) by Using DIOZ as Chiral Auxiliary
Drewes et al. Crystalline, Enantiomerically Pure Aldols from a (‐)‐Ephedrine‐Derived N‐Acylimidazolidin‐2‐one
EP1340743A1 (en) Optically active amine derivative and method of synthesis
WO1995018112A1 (en) Improvements in or relating to chiral auxiliaries
ZA200610148B (en) Preparation of beta-amino acids having affinity for the Alpha-2-Delta protein
Asao et al. Highly stereocontrolled and concise asymmetric synthesis of the β-Lactam framework via a TCC method
CN1515561A (en) Method for producing chiral succinic acid derivative
Sivaprakasam et al. A straightforward synthesis of 3-substituted azetidinic amino acids
KR0182192B1 (en) Selective process for preparing optically active (3r,4s)-3-alkoxy-4-phenyl-2-azetidinone

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995904629

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08663257

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1995904629

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1995904629

Country of ref document: EP